The Sarah Cannon Research Institute/Tennessee Oncology

Nashville, Tennessee 37203

1 studies enrolling now · 8 studies all time

What they study most

Advanced Cancer, Advanced Solid Tumors, Castration-resistant Prostate Cancer, Colorectal Cancer, Colorectal Carcinoma, Cutaneous Melanoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma

Studies at this site

• Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions — Recruiting now
• Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities — Recruiting now
• A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis — Running, not enrolling
• MGD019 DART® Protein in Unresectable/Metastatic Cancer — Completed
• Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors — Stopped early
• Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies — Completed
• GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma — Stopped early
• Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors — Stopped early